Stockscreener 앱 받기
1.67
9.87%
0.15
시간 외 거래:
1.72
0.05
+2.99%
전일 마감가:
$1.52
열려 있는:
$1.51
하루 거래량:
913.08K
Relative Volume:
1.50
시가총액:
$175.96M
수익:
$15.53M
순이익/손실:
$-52.71M
주가수익비율:
-3.3234
EPS:
-0.5025
순현금흐름:
$-59.00M
1주 성능:
+18.44%
1개월 성능:
+5.03%
6개월 성능:
-21.96%
1년 성능:
-11.64%
1일 변동 폭
$1.51
$1.7093
1주일 범위
$1.39
$1.7093
52주 변동 폭
$1.33
$3.10
Proqr Therapeutics N V Stock (PRQR) Company Profile
Compare PRQR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.67 | 164.37M | 15.53M | -52.71M | -59.00M | -0.5025 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-12 | 재개 | Oppenheimer | Outperform |
| 2025-04-29 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-04-29 | 개시 | Evercore ISI | Outperform |
| 2025-03-10 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-01-10 | 개시 | Oppenheimer | Outperform |
| 2024-10-29 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-02-11 | 다운그레이드 | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-02-01 | 개시 | Raymond James | Strong Buy |
| 2021-05-03 | 개시 | Stifel | Buy |
| 2021-03-25 | 재확인 | Citigroup | Buy |
| 2020-11-03 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-03-12 | 재확인 | Chardan Capital Markets | Buy |
| 2018-12-19 | 개시 | RBC Capital Mkts | Outperform |
| 2018-11-15 | 개시 | Citigroup | Buy |
| 2018-09-19 | 개시 | Evercore ISI | Outperform |
| 2017-09-26 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-06-20 | 개시 | Chardan Capital Markets | Neutral |
| 2014-10-15 | 개시 | Deutsche Bank | Buy |
| 2014-10-13 | 개시 | H.C. Wainwright | Buy |
모두보기
Proqr Therapeutics N V 주식(PRQR)의 최신 뉴스
ETFs Investing in ProQR Therapeutics N.V. Stocks - TradingView
ProQR Therapeutics (PRQR) Advances 3% as Biotech Sector Sentiment ImprovesPCR Extreme - newsline.com
Undervalued Penny Stocks To Consider In June 2026 - simplywall.st
Van Herk group (NASDAQ: PRQR) challenges ProQR 2026 AGM share capital proposals - Stock Titan
ProQR Therapeutics N.V. (PRQR) director awarded 14,495 stock options as compensation - Stock Titan
ProQR Shareholders Approve Capital Increase, Board Changes at 2026 AGM - TipRanks
ProQR (PRQR) director Hinsch Gylvin Lykke files Form 3 with no share activity - Stock Titan
ProQR Therapeutics N.V. Appoints Lykke Hinsch Gylvin as Non-Executive Member of the Board, Effective June 2, 2026 - marketscreener.com
PRQR News | PROQR THERAPEUTICS NV (NASDAQ:PRQR) - ChartMill
PRQR Stock Price, Quote & Chart | PROQR THERAPEUTICS NV (NASDAQ:PRQR) - ChartMill
ProQR Therapeutics Holds Steady Above Support; Small Uptick Signals StabilityBullish Pattern Stocks - The Legal Advocate
Citizens reiterates ProQR stock rating on biliary atresia potential By Investing.com - Investing.com Australia
Citizens reiterates ProQR stock rating on biliary atresia potential - Investing.com
ProQR Therapeutics (PRQR) Holds Steady Near $1.57 as Uplift Potential RemainsDaily Profile - The Legal Advocate
ProQR (PRQR) Eyes Next Move After Holiday Ahead of AX-0810 Data - Bez Kabli
ProQR Therapeutics Q1 2026 Earnings: Narrower Net Loss, No Revenue as Pipeline Progress Drives Stock GainsWall Street Picks - Newser
Cash per share of ProQR Therapeutics N.V. – LS:A12B97 - TradingView
ProQR Therapeutics Q1 2026 Earnings: Narrower Loss on Continued Pipeline ProgressEarnings Quality Score - newsline.com
ProQR Therapeutics N.V. (PRQR) Presents at 29th ASGCT Annual Meeting 2026Slideshow - Seeking Alpha
ProQR Therapeutics N.V. (PRQR) Presents at TIDES USA 2026Slideshow (NASDAQ:PRQR) 2026-05-15 - Seeking Alpha
ProQR Therapeutics N.V.Ordinary Shares (NQ: PRQR - The Chronicle-Journal
ProQR Therapeutics N.V. (NASDAQ:PRQR) Analysts Just Slashed This Year's Revenue Estimates By 22% - Yahoo Finance
ProQR Posts Wider Q1 2026 Loss but Maintains Strong Cash Position - The Globe and Mail
ProQR Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
ProQR Posts Q1 2026 Results as Axiomer RNA Editing Pipeline Advances - TipRanks
ProQR Announces First Quarter 2026 Operating and Financial Results - The Manila Times
ProQR (Nasdaq: PRQR) Q1 2026 results, Axiomer pipeline and cash runway - Stock Titan
ProQR (Nasdaq: PRQR) updates AX-0810 strategy and Q1 2026 results - Stock Titan
ProQR Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
TradingKey - TradingKey
ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform - The Manila Times
ProQR Announces Multiple Upcoming Scientific Conference - GlobeNewswire
MSN Money - MSN
Number of shareholders of ProQR Therapeutics N.V. – LS:A12B97 - TradingView
ProQR Therapeutics (PRQR) to Release Quarterly Earnings on Thursday - MarketBeat
ProQR Sets June 2, 2026 Date for Annual General Meeting of Shareholders - The Globe and Mail
ProQR forms advisory board, partnership with Ginkgo as part of AI strategy - MSN
ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026 - markets.businessinsider.com
ProQR Therapeutics NV expected to post a loss of 12 cents a shareEarnings Preview - TradingView
ProQR Therapeutics N : AGM 2026 POA Registered Shareholders - marketscreener.com
ProQR sets June 2 shareholder meeting, posts agenda documents online - Stock Titan
ProQR (PRQR) 2026 AGM to expand share capital, issuance and buyback powers - Stock Titan
ProQR Announces Annual General Meeting of Shareholders to Be Held June 2, 2026 - Moomoo
ProQR Nominates Boehringer Ingelheim CMO Lykke Hinsch Gylvin to Board to Support Next Growth Phase - The Globe and Mail
Proqr Therapeutics N V (PRQR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):